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Previous studies have demonstrated that treatment with activin A and TGF-β1, members of the TGF-β family, stimulated maturation of mouse
bone marrow-derived cultured mast cells (BMMC), which was characterized by morphology and gene expression of mouse mast cell proteases
(mmcps). In order to gain a better understanding of activin A- and TGF-β1-induced maturation in mast cells, we investigated the genes that were
up-regulated in response to treatment with these two members of the TGF-β family. The cDNA microarray analyses indicated that in BMMC, five
genes were induced by treatment with 4 nM activin A for 2 h. Tocopherol-associated protein (Tap) was one of the induced genes, and the Tap
induction in response to activin A treatment was confirmed by real-time RT-PCR analyses. Treatment with TGF-β1 at 200 pM but not BMP-2 at
4 nM also increased Tap gene transcript in BMMC. Activin A-induced Tap expression was detected in BMMC but not in RAW264 macrophage-
like cells, B16 melanoma cells or P19 embryonic carcinoma cells. Treatment with >1 μM SB431542, an inhibitor of activin and TGF-β type I
receptors ALK4/5, reduced responsiveness of Tap expression to TGF-β1, whereas <0.5 μM SB431542 effectively reduced TGF-β1-induced
expression of mmcp-1 and mmcp-7. These results suggest that inhibitory effects of SB431542 are different between TGF-β-induced genes.
Reporter assays indicated that Tap expression enhances transcription mediated by the activin/TGF-β pathway. Thus, the present results suggest
that Tap induction in response to activin/TGF-β occurs predominantly in mast cells and serves as a positive regulator in activin/TGF-β signaling.
© 2006 Elsevier B.V. All rights reserved.Keywords: Activin; TGF-β; Tocopherol-associated protein; Mast cell1. Introduction
Mast cells are involved in inflammatory and immediate
allergic responses. The multivalent binding of an antigen to
receptor-bound IgE and the subsequent aggregation of the high
affinity IgE receptor (FcεRI) provide the trigger for activation of
mast cells, leading to synthesis and secretion of various
enzymes and cytokines related to the immune responses [1].
Mast cells are produced in the bone marrow as progenitor cells.⁎ Corresponding author. Tel.: +81 42 754 7111(276); fax: +81 42 754 7661.
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doi:10.1016/j.bbamcr.2006.06.002These committed precursors of mast cells are present in the
peripheral blood and invade the target tissues [2–4]. Mast cells
maturate in the target tissue under the regulation of local growth
and differentiation factors, resulting in a characteristic mor-
phology with more metachromatic granules and increased
expression of mast cell proteases (mcps) [1,4]. However, our
understanding of mast cell maturation at the molecular level
remains incomplete.
Activins are dimers of inhibin/activin β subunits and are
members of the transforming growth factor-β (TGF-β) super-
family. In common with other members of the TGF-β family
such as TGF-βs and bone morphogenetic proteins (BMPs),
activins are potent growth and differentiation factors that
perform various physiological activities [5,6]. Previously, we
Fig. 1. Activin A and TGF-β1 but not BMP-2 increase Tap gene transcript in
mast cells. BMMC, RAW264 macrophage-like cells, B16 melanoma cells and
P19 embryonic carcinoma cells were cultured with activin A (4 nM), TGF-β1
(200 pM) and BMP-2 (4 nM) for 24 h. Ligand was added to α-MEM with 10%
FCS and 10% PWM-SCM in BMMC, DMEM with 10%FCS in RAW264 and
P19 cells, and RPMI1640 with 10% FCS in B16 cells. Real-time quantitative
RT-PCR was performed. The mRNA level of Tap was expressed relative to
G3pdh. The level of mRNA in the absence of ligand was assigned a value of 1.
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βA) stimulated the morphological changes toward maturated
mast cells, and increased gene expression of mcps in mouse
bone marrow-derived cultured mast cells (BMMC) [7–9]. As
activin A is up-regulated in mast cells in response to activation
[10,11], it may play a significant role in the immune responses
mediated by mast cells. In order to understand activin-induced
maturation of mast cells in greater detail, we examined the
genes induced in response to activin A treatment in BMMC.
2. Materials and methods
2.1. Materials
Recombinant activin Awas kindly provided by Dr. A.F. Parlow through the
National Pituitary and Hormone Distribution Program at NIDDK. Purified
TGF-β1 and recombinant BMP-2 were purchased from Becton Dickinson and
R&D Systems, respectively. The OMM13K oligonucleotide arrays containing
13,443 70-mer single-stranded oligonucleotides from mouse genes were
purchased from the Keck DNA Array Facility at Yale University. SB431542,
an ALK4/5 inhibitor [12,13], was purchased from TOCRIS. PD98059, a
MEK1 inhibitor [14], and SB203580, a p38 kinase inhibitor [15], were
purchased from Calbiochem. SP600125, a JNK inhibitor [16], was purchased
from BIOMOL Research Laboratories (Plymouth Meeting, PA).
2.2. cDNA constructs
Plasmids were obtained as follows: constitutively active ALK5 (ALK5-TD),
with Thr 204 replaced by Asp [17], from Dr. X.-F. Wang, mmcp-7(−185 to
+20)-luc [18] from Drs. Y. Kitamura and E. Morii, PAI-1(−800 to +76)-luc [19]
from Drs. H.F. Lodish and X. Hua, FoxH3 [20] and AR3-luc [21] from Dr. M.
Whitman and HA-pcDNA3 expression vector [22] from Dr. N. Inohara and T.
Koseki. Human inhibin/activin βA cDNA was subcloned into pcDNA3 using
the XhoI site. Mouse Tap cDNA containing BamHI and SalI restriction enzyme
sites at the 5′- and 3′-ends, respectively, was subcloned into the BamHI and
XhoI sites of HA-pcDNA3 to produce C-terminal HA-tagged Tap.
2.3. Animals and cell culture
BALB/c mice were obtained from SLC (Shizuoka, Japan). We used mice
with a deletion of Smad3 exon 8, generated through homologous recombination
[23]. Litters were produced by mating mice heterozygous for the targeted Smad3
deletion with those from a mixed 129/C57BL/6 background. Genotyping of the
offspring was performed as described previously [23]. Mice were cared for
according to the principles outlined in the Institute for Laboratory Animal
Research Guide for the Care and Use of Laboratory Animals [24].
BMMC were cultured from the bone marrow cells of 6- to 8-week-old mice
as described previously [7]. More than 95% of the trypan blue-excluding viable
cells were identified as mast cells based on staining with acid toluidine. BMMC
were grown in α-MEM containing 10% FBS and 10% pokeweed mitogen-
stimulated spleen cell-conditioned medium (PWM-SCM). For ligand stimula-
tion experiments, BMMC (2.5×106 cells/ml) were incubated with activin A atTable 1






BC005759 Tocopherol-associated protein 4.32 0.15
NM_023719 Thioredoxin interacting protein 3.42 1.73
X78543 MCP-Y1 3.37 0.31
AK017885 Rho-related GTP-binding protein rho H 1.78 0.25
BC005481 Elastin microfibril interface located protein 1 1.62 0.104 nM (or the indicated concentration), TGF-β1 at 200 pM, or BMP-2 at 4 nM for
2 h (or specified time period) in α-MEM with 10% FBS and 10% PWM-SCM.
For some experiments, BMMC were preincubated with vehicle (DMSO) or
SB431542 at the indicated concentration for 20 min. Then, TGF-β1 (200 pM)
was added to the medium for 24 h. In addition, for some experiments, BMMC
were incubated with TGF-β1 (200 pM) for 8 h in α-MEM with 10% FBS and
10% PWM-SCM after preincubation with vehicle (DMSO), PD98059 (50 μM),
SB203580 (5 μM) or SP600125 (20 μM) for 20 min. The kinase inhibitors
(PD98059, SB203580 and SP600125) were applied at concentrations known to
inhibit their respective protein kinases [14–16], and were not washed out of the
medium. Furthermore, for some experiments, BMMC were preincubated withFig. 2. TGF-β1 increases Tap transcript levels in mast cells. (A) Time-course
changes in Tap expression in response to activin A, TGF-β1 and BMP-2.
BMMC were cultured with activin A (4 nM), TGF-β1 (200 pM) and BMP-2
(4 nM) in α-MEM with 10% FCS and 10% PWM-SCM for the indicated time.
(B) Effects of a protein synthesis inhibitor cycloheximide on TGF-β1-induced
Tap expression. BMMC were treated with or without TGF-β1 (200 pM) in the
presence (+) or absence (−) of cycloheximide (0.5 μg/ml) for 12 h. Real-time
quantitative RT-PCR was performed. The mRNA level of Tap was expressed
relative to G3pdh. The level of mRNA in the absence of ligand and cyc-
loheximide was assigned a value of 1.
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with TGF-β1 (200 pM) for 12 h.
RAW264 macrophage-like cells and HepG2 hepatoma cells were provided
by the RIKEN Cell Bank, and B16 melanoma cells and P19 embryonic
carcinoma cells were provided by the Institute of Development, Aging and
Cancer, Tohoku University. RAW264 and HepG2 cells were cultured in DMEM
with 10% FBS. P19 cells were cultured in α-MEM with 6% FBS, and B16 cells
were cultured in RPMI1640 with 10% FBS. In addition, all cell culture media
contained 100 U/ml penicillin and 100 μg/ml streptomycin. Transient
transfections were performed using PolyFect (Qiagen) for HepG2 and P19
cells, and SuperFect (Qiagen) for B16 cells.
2.4. cDNA microarray
BMMC (2.5×106/ml) were treated with or without activin A (4 nM) for 2 h
in α-MEM with 10% FBS and 10% PWM-SCM. Total RNAwas isolated using
an RNA isolation kit (RNeasy, Qiagen). Total RNA (20 μg) was reverse-
transcribed using oligo-dT and labeled in a total volume of 20 μl using
CyScribe First-Strand cDNA Labelling Kit (Amersham Biosciences), accord-Fig. 3. Inhibition of TGF-β1-induced expression by the ALK4/5/7 inhibitor SB43154
β1 (200 pM) for 24 h after pretreatment with the indicated concentrations of SB43154
of Tap (A), mmcp-1 (B) and mmcp-7 (C) were expressed relative to G3pdh. The leving to the manufacturer's protocol. Once the reaction was complete, the
template RNA was hydrolyzed by incubation with 2 μl of 2.5 M NaOH for
15 min at 37 °C. After adding 10 μl of 2 M HEPES, unconjugated dye was
removed using a GFX column (Amersham Biosciences). Cy3- and Cy5-labeled
probes were combined and finally resuspended in 5 μl of dH2O. The probes
were incubated for 2 min at 94 °C, followed by incubation on ice for 30 s To
block non-specific binding of the poly-T tail in probes, 1.25 μl of oligo A
(0.8 mg/ml) was added and incubated for 45 min at 75 °C. The glass slide
arrays, OMM13K containing 13,443 mouse genes, were prehybridized for
45 min at 50 °C in hybridization buffer (Amersham Biosciences) containing
50% formamide, followed by hybridization for 18 h at 43 °C. Arrays were
washed in 1×SSC/0.2% SDS for 10 min, followed by two 10-min washes in
0.1×SSC/0.2% SDS and finally in dH2O for 10 s Arrays were dried and
scanned at 532 and 635 nm using a GenePix4000A (Axon Instruments, Foster
City, CA). Experiments were performed twice using independent cell samples
and different dyes were used as the label between experiments. After
normalization by linear regression scaling, the ratio of medians was evaluated.
Genes that responded to treatment with activin A with ≥1.5-fold increased
expression were evaluated further.2. BMMC from wild-type or Smad3-null mice were treated with or without TGF-
2 for 20 min. Real-time quantitative RT-PCR was performed. The mRNA levels
el of mRNA in the absence of ligand and SB431542 was assigned a value of 1.
Fig. 4. Inhibition of TGF-β1-induced expression by kinase inhibitors of the
MAP kinase pathway. BMMC from wild-type mice were treated with or without
TGF-β1 (200 pM) for 8 h after pretreatment with vehicle (DMSO), PD98059
(50 μM), SB203580 (5 μM) or SP600125 (20 μM) for 20 min. Real-time
quantitative RT-PCR was performed. The mRNA levels of Tap were expressed
relative to G3pdh. The level of mRNA in the absence of ligand and kinase
inhibitor was assigned a value of 1. *P<0.05 as compared with TGF-β1 (−);
†P<0.05 as compared with TGF-β1 (+) in the absence of kinase inhibitors.
903M. Funaba et al. / Biochimica et Biophysica Acta 1763 (2006) 900–9062.5. Real-time RT-PCR
Real-time RT-PCR was conducted as described previously [8]. Oligonucleo-
tide primers for mmcp-7 and G3pdh were described as previously [8]. For the
Tap and mmcp-1 gene transcripts (GenBank accession numbers BC005759
and NM_008570, respectively), oligonucleotides encoding positions from 785
to 806 and 853 to 834 for Tap, and those from 341 to 365 and 424 to 403 for
mmcp-1 were designed. Levels of Tap, mmcp-1, mmcp-7 and G3pdh expression
in each sample were determined using the relative standard curve method. The
relative amount of DNA of Tap, mmcp-1 and mmcp-7 was expressed as a ratio
to that of G3pdh DNA. The Tap, mmcp-1 and mmcp-7 level in BMMC without
stimulation with ligands and inhibitors was given a value of 1.
2.6. Reporter assay
Luciferase-based reporter assays were conducted as described previously
[8]. Cells were transiently transfected with the indicated expression vectors,
reporter construct, or a plasmid expressing β-galactosidase (pCMV-βGal).
Equal amounts of DNAwere transfected in each experiment and adjusted with
pcDNA3. Cells were harvested 40 h after transfection. Luciferase activity was
normalized against β-galactosidase activity, and the luciferase activity in the cell
lysate in the absence of activin βA, ALK5-TD or Tap was assigned a value of 1.
3. Results
To examine initial events induced by activin A treatment in
mast cells, we performed cDNA microarray analyses using
BMMC. Results from two independent experiments indicated
that only five genes were up-regulated by treatment with activin
A (4 nM) for 2 h in both experiments (Table 1). Activin A-
induction of these genes was confirmed using semi-quantitative
RT-PCR (data not shown); in both assays the Tap gene
transcript exhibited the greatest response. Tap encodes a protein
containing two conserved domains [25]: CRAL/TRIO, which is
predicted to form a pocket for binding a small hydrophobic
ligand; and GOLD, which is thought to modulate Golgi function
or trafficking through protein–protein interaction.
Previous study has shown that in BMMC the activity of
activin A depends upon its concentration, i.e., changes in
morphology and expression of mmcp are affected by nanomolar
concentrations, whereas migration toward activin A is observed
at lower concentrations [7]. Competitive RT-PCR analyses
indicated that treatment of both BMMC and MC/9 mast cells
with activin A at 4 nM but not at 0.1 nM resulted in an increase
in Tap transcript (data not shown). In addition, real-time RT-PCR
analyses indicated that treatment with TGF-β1 (200 pM) but
not BMP-2 (4 nM) resulted in increased Tap transcript levels
(Fig. 1). In cells unrelated to mast cells, i.e., RAW264, B16 and
P19 cells, activin A-induced expression of Tap was not
detected, and expression was not induced by the ligands
TGF-β1 or BMP-2 (Fig. 1).
Time-course changes in Tap gene transcript were next
examined in BMMC (Fig. 2A). Treatment with activin A
increased Tap gene transcript within 2 h and the increased gene
transcript continued at least for 24 h. Similar to activin A,
treatment with TGF-β1 resulted in a prolonged effect on gene
induction of Tap (Fig. 2A). Up-regulation of Tap by BMP-2
treatment was not seen at any tested time. Because of the limited
availability of activin A, the remaining work was carried out by
use of TGF-β1 as the agonist. Previous studies have indicatedthat TGF-β1 and activin A elicit similar activities in BMMC
including cell growth inhibition, morphological changes,
migration and regulation of gene expression [7,8,26]. At present
activin signaling is indistinguishable from TGF-β signaling at
the signaling molecule level of downstream of receptor binding;
activin and TGF-β signal via membrane-bound heteromeric
serine kinase receptor complexes. Upon ligand binding to
respective type II receptor, the type II receptor recruits,
phosphorylates and activates the type I receptor (ALK4 for
activin, and ALK5 for TGF-β). The activated type I receptor
serine kinases phosphorylate Smad2/3, leading to complex
formation with Smad4 and regulation of target gene transcrip-
tion [27,28].
In order to determine whether de novo protein synthesis is
required for Tap induction, effect of a protein synthesis inhibitor
cycloheximide was examined. As shown in Fig. 2B, treatment
with cycloheximide did not block the TGF-β1-induced Tap
expression. The cycloheximide treatment rather increased Tap
expression, although responses to TGF-β1 were smaller in
the presence of cycloheximide than in the absence of
cycloheximide.
Using BMMC from wild-type and Smad3-null mice and an
ALK4/5 inhibitor SB431542, we evaluated the involvement of
the type I receptor and Smad3 in TGF-β1-induced Tap
expression. Previous studies have shown that treatment with
TGF-β resulted in the increases in gene transcript of mmcp-1
and mmcp-7 in BMMC [7,8,29]. Inhibitory effect of SB431542
on TGF-β1-induced Tap gene transcript was compared with that
on TGF-β1-induced mmcp-1 and mmcp-7 genes. TGF-β1-
induced Tap gene transcript was partially repressed in the
presence of SB431542 in a dose-dependent manner in wild-type
BMMC, and the IC50 concentration of SB431542 was 10.61±
3.75 (mean±S.E.) μM (Fig. 3A). As compared with the effect of
SB431542 on Tap expression, the inhibitor repressed TGF-β1-
induced mmcp-1 and mmcp-7 genes more efficiently in wild-
type BMMC: the IC50 of SB431542 was 0.45±0.10 μM for
904 M. Funaba et al. / Biochimica et Biophysica Acta 1763 (2006) 900–906mmcp-1 gene and 1.81±0.90 μM for mmcp-7 (Fig. 3B, C). In
Smad3-null BMMC, treatment with TGF-β1 also increased
expression of Tap, mmcp-1 and mmcp-7, although the extent
tended to be smaller (Fig. 3). Effects of SB431542 in Smad3-
null BMMC were comparable with those in wild-type BMMC,
i.e., less effective inhibition of Tap expression (IC50 (μM):
7.33±4.79), and efficient inhibition of mmcp-1 (IC50 (μM):
0.36±0.03) and mmcp-7 (IC50 (μM): 2.09±0.27).
In addition, we examined the effects of MAP kinase
pathway, since activin/TGF-β and MAP kinase pathways are
closely related [27,28]. Although none of the inhibitors
(PD98059, SB203580 or SP600125) completely abrogated
TGF-β1-induced Tap in either wild-type or Smad3-null
BMMC, induction was partially repressed by treatment with
PD98059 and significantly reduced with SP600125 in BMMCFig. 5. Expression of Tap enhances activin/TGF-β-mediated transcriptional activatio
were transiently transfected with mmcp-7-luc, PAI-1-luc and AR3-luc, respectivel
constitutively active TGF-β receptor, ALK5-TD (B, C). For P19 cells, FoxH3 plasmid
activity was normalized to β-galactosidase activity. Luciferase activity in the cell lysa
representative result from three independent experiments is shown. Data are express(Fig. 4). In Smad3-null BMMC, inhibitory effect of kinase
inhibitor on TGF-β1-induced Tap gene was hardly detected
(data not shown).
To elucidate possible role for Tap induced by treatment with
activin A and TGF-β1, we examined effects of Tap expression
on activin/TGF-β signaling using HepG2 cells, B16 cells and
P19 cells, which are known to be responsive to these ligands
[9,30–32]. As Tap is not induced by treatment with these
ligands in B16 cells and P19 cells (Fig. 1), the effects of
exogenous Tap on the activin/TGF-β pathway could be clearly
evaluated. Luciferase-based reporter assays using mmcp-7-luc,
PAI-1-luc and AR3-luc, revealed that Tap enhanced transcrip-
tion of expression of these reporters induced by expression of
activin βA (Fig. 5A) or constitutively active ALK5 (ALK5-TD)
(Fig. 5B). In fact, ALK5-TD-induced transcriptional activationn. Along with β-galactosidase expression plasmid, HepG2, B16 and P19 cells
y. Cells were also transfected with or without Tap and activin βA (A) and a
was also transfected. At 40 h after transfection, cells were harvested. Luciferase
tes in the absence of activin βA, ALK5-TD and Tap was assigned a value of 1. A
ed as the mean±SD (n=3).
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(Fig. 5C).
4. Discussion
The present study indicates that: (1) activin A and TGF-
β1 increase expression of Tap in murine mast cells; (2) activin/
TGF-β-induced Tap is limited to mast cells; and (3) the induced
Tap acts as a positive modulator for activin/TGF-β signaling.
Mast cell-specific up-regulation of Tap in response to activin/
TGF-β explains one of the reasons of diverse physiological
activities of members of the TGF-β family irrespective of
relatively simple signaling mechanism described above: activin
and TGF-β induce modulator genes of themselves in a cell type-
specific manner.
Experiments using the protein synthesis inhibitor cyclohe-
ximide indicated that de novo synthesis was not required for
induction of Tap, suggesting a direct effect of activin/TGF-β.
Because members of the TGF-β family phosphorylate and
activate various MAP kinases [27,28], it is possible that the
MAP kinases regulate Tap induction. Experiments using MAP
kinase inhibitors indicated the partial inhibition of the Tap
induction by treatment with the kinase inhibitor, especially
PD98059 and SP600125, in wild-type BMMC but not Smad3-
null BMMC, suggesting a functional interaction between the
Smad3 pathway and the MAP kinase (in particular the ERK and
JNK) pathways.
We observed significant induction of Tap in response to the
TGF-β1 treatment in both Smad3-null and wild-type BMMC,
although the level of induction was lower in the former. These
results suggest that the involvement of Smad3 in activin/TGF-
β-induced Tap is limited, and imply the presence of an as yet
unidentified induction pathway. Increased expression of Smad2
has been reported in the liver of Smad3-null mice [33], and thus,
it is possible that expression of Smad2 increases in Smad3-null
BMMC, and compensates for the lack of Smad3-mediated
signaling. However, we did not observe a significant increase in
Smad2 expression in Smad3-null BMMC (data not shown).
Induction of Tap by activin/TGF-β was also inhibited by the
ALK4/5 inhibitor SB431542, suggesting that this process is
mediated through activated activin/TGF-β receptor complexes.
However, the concentration of SB431542 required for efficient
inhibition of Tap induction was higher than for either mmcp-1
or mmcp-7. It may be possible that Tap is induced through both
an activated ALK4/5-mediated mechanism and an ALK4/5-
independent mechanism. Alternatively, it is possible that a
limited number of activated ALK4/5 receptor complexes is
sufficient for induction of Tap, relative to the requirement for
induction of mmcp-1 and mmap-7. However, the latter is
unlikely, because the minimum concentration of ligand required
for significant induction of mmcp-1 and mmcp-7 was lower
than for Tap (data not shown). SB431542 weakly inhibits p38
kinase in vitro [13], and thus, the partial inhibition of Tap
induction at higher SB431542 concentrations may be the result
of inhibition of p38 kinase. However, this is also unlikely, since
treatment of wild-type BMMC with SB203580 effectively
blocked TGF-β1-induced activation of p38 (data not shown) butdid not inhibit Tap induction significantly. Taken together, the
results indicated that Tap induction occurs through both an
integrated pathway involving ALK4/5, Smad3 and MAP
kinases and an as yet unspecified ALK4/5-independent path-
way. Clearly, further definitive studies are needed to elucidate
this point.
The Tap has been independently identified as a molecule
with activities including binding to α-tocopherol [34], transport
of phosphatidylinositol [35], transport of squalene for choles-
terol biosynthesis [36], although the physiological role is not
clear yet. In addition to these activities, Tap has been recently
shown to possess GTPase activity [37], and to inhibit the
phosphoinositide 3-kinase pathway required for growth arrest in
cancer cells [38]. Furthermore, CGP-1, a protein with the
CRAL/TRIO domain and the GOLD domain, was involved in
the Ras signaling pathway in C. elegans [39]. In addition to
these activities, the present study revealed that Tap enhanced the
activin/TGF-β pathway. This protein with the CRAL/TRIO and
GOLD domain may be involved in the regulation of many
biological processes in a wide variety of organisms, from ne-
matodes to vertebrates.
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